CU hopes that the FDA will support legislation in Congress during the PDUFA user fee debate and the debate on Kennedy-Enzi (S. 484) to add language that will strengthen the requirements for timely, mandatory pre-approval of ads, civil monetary penalties for violations (especially repeat violations), and the more frequent placement of corrective ads so as to prevent abuse.